Seth Lederman - Mar 25, 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Stock symbol
TNXP
Transactions as of
Mar 25, 2022
Transactions value $
$24,500
Form type
4
Date filed
3/28/2022, 08:00 AM
Previous filing
Feb 17, 2022
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, $0.001 par value Purchase $24.5K +100K +821.22% $0.25 112K Mar 25, 2022 Direct
holding TNXP Common Stock, $0.001 par value 135K Mar 25, 2022 By 401(k) plan
holding TNXP Common Stock, $0.001 par value 459 Mar 25, 2022 By IRA Account
holding TNXP Common Stock, $0.001 par value 31 Mar 25, 2022 By spouse
holding TNXP Common Stock, $0.001 par value 30 Mar 25, 2022 By Leder Laboratories, Inc. F1
holding TNXP Common Stock, $0.001 par value 30 Mar 25, 2022 By Starling Pharmaceuticals, Inc. F1
holding TNXP Common Stock, $0.001 par value 205 Mar 25, 2022 By Lederman & Co., LLC F1
holding TNXP Common Stock, $0.001 par value 33 Mar 25, 2022 By L&L Technologies, LLC F1
holding TNXP Common Stock, $0.001 par value 59 Mar 25, 2022 By Targent Pharmaceuticals, LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting person may be deemed to be a control person of this entity.